DK1162981T3 - Dexrazoran til behandling af utilsigtet ekstravasation af anthracycliner - Google Patents
Dexrazoran til behandling af utilsigtet ekstravasation af anthracyclinerInfo
- Publication number
- DK1162981T3 DK1162981T3 DK00910564T DK00910564T DK1162981T3 DK 1162981 T3 DK1162981 T3 DK 1162981T3 DK 00910564 T DK00910564 T DK 00910564T DK 00910564 T DK00910564 T DK 00910564T DK 1162981 T3 DK1162981 T3 DK 1162981T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- anthracyclines
- extravasation
- dexrazoran
- topoisomerase
- Prior art date
Links
- 206010015866 Extravasation Diseases 0.000 title abstract 4
- 230000036251 extravasation Effects 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 4
- 229940045799 anthracyclines and related substance Drugs 0.000 title abstract 3
- 239000002574 poison Substances 0.000 abstract 3
- 231100000614 poison Toxicity 0.000 abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 abstract 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 abstract 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 abstract 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 abstract 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 abstract 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 abstract 1
- 101710183280 Topoisomerase Proteins 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 229960000975 daunorubicin Drugs 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229960001904 epirubicin Drugs 0.000 abstract 1
- 229960000908 idarubicin Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011458 pharmacological treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical And Physical Treatments For Wood And The Like (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199900355 | 1999-03-12 | ||
| EP00910564A EP1162981B1 (fr) | 1999-03-12 | 2000-03-13 | Dexrazoxane pour le traitement d'epanchement accidentel d'anthracyclines |
| PCT/DK2000/000107 WO2000054782A1 (fr) | 1999-03-12 | 2000-03-13 | Traitement d'epanchement accidentel d'anthracyclines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1162981T3 true DK1162981T3 (da) | 2004-08-16 |
Family
ID=8092594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00910564T DK1162981T3 (da) | 1999-03-12 | 2000-03-13 | Dexrazoran til behandling af utilsigtet ekstravasation af anthracycliner |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6727253B2 (fr) |
| EP (2) | EP1162981B1 (fr) |
| JP (1) | JP4422916B2 (fr) |
| CN (1) | CN1199644C (fr) |
| AT (1) | ATE265215T1 (fr) |
| AU (1) | AU769533B2 (fr) |
| BR (1) | BR0009473A (fr) |
| CA (1) | CA2367240C (fr) |
| DE (2) | DE60010241T2 (fr) |
| DK (1) | DK1162981T3 (fr) |
| ES (1) | ES2220424T3 (fr) |
| HK (1) | HK1043054B (fr) |
| MX (1) | MXPA01009212A (fr) |
| NO (1) | NO327354B1 (fr) |
| PT (1) | PT1162981E (fr) |
| RU (1) | RU2252761C2 (fr) |
| WO (1) | WO2000054782A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60209471D1 (de) * | 2001-03-29 | 2006-04-27 | Topo Target As Copenhagen Koeb | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii |
| WO2007062076A2 (fr) * | 2005-11-23 | 2007-05-31 | Novartis Ag | Formulations de dexrazoxane et methodes associees |
| ES2993327T3 (en) * | 2014-08-06 | 2024-12-27 | Ascendis Pharma As | Prodrugs comprising an aminoalkyl glycine linker |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963551A (en) * | 1987-12-21 | 1990-10-16 | Erbamont Inc. | Stable lyophilized form of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and solutions thereof |
| US5242901A (en) * | 1988-01-27 | 1993-09-07 | New York University | Reduction of anthracycline induced cardiotoxicity |
| GB9122720D0 (en) * | 1991-10-25 | 1991-12-11 | Holthuis Josephus J M | (s)(+)-4,4'-(1-methyl-1,2-ethanediyl)-bis(2,6-piperazinedione)formulations and their preparation |
| WO1993021938A1 (fr) * | 1992-05-04 | 1993-11-11 | Adria Laboratories | Procedes de traitement du cancer au moyen de l'epirubicine a haute dose |
| WO1993023075A1 (fr) | 1992-05-14 | 1993-11-25 | Oncologix, Inc. | Traitement du syndrome de permeabilite capillaire diffuse et des maladies induites par la collagenase par administration d'inhibiteurs de la metalloproteinase matricielle |
| US5620961A (en) * | 1994-04-25 | 1997-04-15 | Markovic; Nenad S. | Fructose ester-β-cyclodextrin complexes and processes for making and using same |
| ES2205164T3 (es) * | 1996-01-11 | 2004-05-01 | Topotarget Aps | Terapia combinada de toxinas de topoisomerasa ii con derivados de bis-dioxipiperazina. |
| FR2758264B1 (fr) | 1997-01-16 | 1999-03-26 | Charles Dumontet | Compositions medicamenteuses contenant de l'edta ou un de ses derives pour la prevention de la toxicite cutanee et sous-cutanee des anthracyclines et de leurs derives |
| WO1998041202A1 (fr) | 1997-03-20 | 1998-09-24 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Metabolites d'hydroxybenzoate et analogues d'hydroxybenzoate en tant que protecteurs contre le stress oxydatif, la cytotoxicite provoquee par des medicaments chimiotherapiques, la cardiotoxicite et les lesions tissulaires causees par un epanchement |
-
2000
- 2000-03-13 ES ES00910564T patent/ES2220424T3/es not_active Expired - Lifetime
- 2000-03-13 EP EP00910564A patent/EP1162981B1/fr not_active Expired - Lifetime
- 2000-03-13 RU RU2001127663/15A patent/RU2252761C2/ru active
- 2000-03-13 AU AU32726/00A patent/AU769533B2/en not_active Expired
- 2000-03-13 JP JP2000604858A patent/JP4422916B2/ja not_active Expired - Fee Related
- 2000-03-13 AT AT00910564T patent/ATE265215T1/de active
- 2000-03-13 EP EP04076271A patent/EP1459752A3/fr not_active Withdrawn
- 2000-03-13 BR BR0009473-0A patent/BR0009473A/pt not_active Application Discontinuation
- 2000-03-13 WO PCT/DK2000/000107 patent/WO2000054782A1/fr not_active Ceased
- 2000-03-13 CN CNB00806167XA patent/CN1199644C/zh not_active Expired - Lifetime
- 2000-03-13 DK DK00910564T patent/DK1162981T3/da active
- 2000-03-13 CA CA2367240A patent/CA2367240C/fr not_active Expired - Lifetime
- 2000-03-13 DE DE2000610241 patent/DE60010241T2/de not_active Expired - Lifetime
- 2000-03-13 MX MXPA01009212A patent/MXPA01009212A/es active IP Right Grant
- 2000-03-13 HK HK02104568.2A patent/HK1043054B/en not_active IP Right Cessation
- 2000-03-13 DE DE1162981T patent/DE1162981T1/de active Pending
- 2000-03-13 PT PT00910564T patent/PT1162981E/pt unknown
-
2001
- 2001-06-29 US US09/893,521 patent/US6727253B2/en not_active Expired - Lifetime
- 2001-09-12 NO NO20014433A patent/NO327354B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2367240C (fr) | 2010-11-16 |
| MXPA01009212A (es) | 2004-04-23 |
| US20020099057A1 (en) | 2002-07-25 |
| DE60010241D1 (de) | 2004-06-03 |
| AU769533B2 (en) | 2004-01-29 |
| EP1459752A2 (fr) | 2004-09-22 |
| PT1162981E (pt) | 2004-09-30 |
| NO327354B1 (no) | 2009-06-15 |
| CN1346275A (zh) | 2002-04-24 |
| AU3272600A (en) | 2000-10-04 |
| CN1199644C (zh) | 2005-05-04 |
| ES2220424T3 (es) | 2004-12-16 |
| US6727253B2 (en) | 2004-04-27 |
| WO2000054782A1 (fr) | 2000-09-21 |
| NO20014433L (no) | 2001-11-06 |
| EP1459752A3 (fr) | 2007-07-18 |
| JP2002539168A (ja) | 2002-11-19 |
| EP1162981B1 (fr) | 2004-04-28 |
| HK1043054B (en) | 2004-12-17 |
| NO20014433D0 (no) | 2001-09-12 |
| ATE265215T1 (de) | 2004-05-15 |
| HK1043054A1 (en) | 2002-09-06 |
| CA2367240A1 (fr) | 2000-09-21 |
| EP1162981A1 (fr) | 2001-12-19 |
| RU2252761C2 (ru) | 2005-05-27 |
| DE1162981T1 (de) | 2002-05-23 |
| BR0009473A (pt) | 2001-11-27 |
| DE60010241T2 (de) | 2005-01-13 |
| JP4422916B2 (ja) | 2010-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1127572A3 (fr) | Utilisation de flavones dans le traitement de maladies induites par cyclooxygenase-2 | |
| BR9908391A (pt) | Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina | |
| BR0008453A (pt) | Composição sinergìstica anti-tumoral | |
| CA2436799A1 (fr) | Combinaisons de medicaments (par exemple de chlorpromazine et de pentamidine) pour le traitement de troubles neoplasiques | |
| DK0841949T3 (da) | Anvendelse af saccharid-konjugater | |
| ES2091727B1 (es) | Formulaciones de analogos de insulina. | |
| DK0740668T3 (da) | Tetracykliske derivater, fremgangsmåde til deres fremstilling og deres anvendelse | |
| AR028959A1 (es) | Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares | |
| AU4830097A (en) | Use of an extract of Cimicifuga | |
| DK1162981T3 (da) | Dexrazoran til behandling af utilsigtet ekstravasation af anthracycliner | |
| WO2006046080A3 (fr) | Traitements anticancereux | |
| AU5917390A (en) | Pharmaceutical composition for topic use for the therapeutical treatment of capillary fragility | |
| PT994697E (pt) | Formulacoes de rapamicina para administracao oral | |
| PT1086682E (pt) | Utilizacao de derivados de arilo(ou heteroaril)azolil-carbinol na preparacao de um medicamento para o tratamento de inflamacao neurogenica | |
| BR9913627A (pt) | Uso de um derivado de antraciclina para o tratamento de um tumor no fìgado | |
| BR0016720A (pt) | Uso de trimebutina para tratamento de dores | |
| WO2000050033A3 (fr) | Composition synergique anti-tumorale | |
| AU6404798A (en) | Pharmaceutical composition for the administration of thiocolchicoside via the buccal mucosa | |
| PT874630E (pt) | Terapia combinada de um inibidor da topoisomerase ii e um derivado da bis-dioxipiperazina | |
| NO830234L (no) | Daunorubicin- og doxorubicinanaloger, deres fremstilling og bruk. | |
| WO2001070093A3 (fr) | Agents et procedes conçus pour la prevention des premiers signes de cancers, le traitement de cancers et la recurrence de cancers existants | |
| PT1200099E (pt) | Composicao sinergetica compreendendo derivados de daunorubicina e compostos antimetabolito | |
| DE69008282D1 (de) | Kaffeesäure-Derivate, deren Verwendung für medizinische Behandlungen und diese enthaltende pharmazeutische Zusammensetzungen. | |
| BR9704686B1 (pt) | composição farmacêutica contendo grupos de bactérias, e uso da mesma para impedir e tratar doenças associadas com, ou causadas pelo metabolismo alterado de ácido de bìlis. | |
| AU2002210512A1 (en) | Treatment of tinnitus |